Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10682496			
Filing Date		2006-08-24			
First Named Inventor	Xiao-	-Yı Xiao			
Art Unit		1626			
Examiner Name	Andre	ew B. Freistein			
Attorney Docket Numb	er	HDAC-5003-U			

	U.S.PATENTS								Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	te Name of Patentee or Applicant R			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee of Applicant Reli		Releva	Columns,Lines when ant Passages or Release Appear	
	1	20040053820				Nakajima, Hidenon et al.				
	2	20050277583				Yoshida, Mino	da, Minoru et al.			
	3	20050272647		2005-1	2-08	YAMAJI, Noboru et al.				
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d button		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	Ts
	1	EP 1547617 A1	EP			2006-06-29	Yamanouchi Pharmaceutical Co	.		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10682496
Filing Date		2006-08-24
First Named Inventor	Xiao-	Yı Xiao
Art Unit		1626
Examiner Name	Andre	ew B. Freistein
Attorney Docket Numb	er	HDAC-5003-U

JAPAN ENERGY

Date Considered

	2	EP1010705A1	l P		2000-06-21	CORPORATION		ш			
	3	EP1548026A1	EP		2005-06-29	YAMANOUCHI PHARMACEUTICAL CO.					
	4	WO/03075839	wo		2003-09-18	ATON PHARMA, INC.					
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	lease click the Add butto	n Add				
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove				
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.										
	1 Patent Abstracts of Japan – JP 2000256397A, Fied 09-19-2000; Japan Energy Corporatin, Nishino Norikazu et al.										
2 Patent Abstracts of Japan – JP 09071566, Filed 03/16/1997; Elsas Co., LTD, Korchi, Kliuchi et al.											
	3 English Abstract of PCT Publication # WO 03/07/691 A1, Filed 8/29/2003, OSAKA INDUSTRIAL PROMOTION ORGANIZATION, Shiraichi UESATO et al.										
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add										
EYAMINED SIGNATI IDE											

1 See Knot Codes of USPTO Point Documents at week USPTO.COV or MPEP 901.04. 2 finite ordice that issued the document, by the Involetor code (WIPO Standard ST3). 3 for Juniprises plant for Juniprises that Ju

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include conv of this form with next communication to applicant.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10682496
Filing Date		2006-08-24
First Named Inventor	Xiao-	Yı Xiao
Art Unit		1626
Examiner Name	Andre	ew B. Freistein
Attorney Docket Numb	er	HDAC-5003-U

CERTIFICATION STATEMENT

Please see	37	CFR	1 97	and	1.98 to	make th	e appro	nriate	selection	(s)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sidelosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David J. Wertz/	Date (YYYY-MM-DD)	2006-08-25						
Name/Print	David J. Weitz	Registration Number	38.362						

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.